Kjeldsen Emilie W, Thomassen Jesper Q, Juul Rasmussen Ida, Nordestgaard Børge G, Tybjærg-Hansen Anne, Frikke-Schmidt Ruth
Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.
The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark.
Cardiovasc Res. 2022 Mar 25;118(5):1330-1343. doi: 10.1093/cvr/cvab164.
The association of plasma high-density lipoprotein (HDL) cholesterol with risk of dementia is unclear. We, therefore, tested the hypothesis that high levels of plasma HDL cholesterol are associated with increased risk of dementia and whether a potential association is of a causal nature.
In two prospective population-based studies, the Copenhagen General Population Study and the Copenhagen City Heart Study (N = 111 984 individuals), we first tested whether high plasma HDL cholesterol is associated with increased risk of any dementia and its subtypes. These analyses in men and women separately were adjusted multifactorially for other risk factors including apolipoprotein E (APOE) genotype. Second, taking advantage of two-sample Mendelian randomization, we tested whether genetically elevated HDL cholesterol was causally associated with Alzheimer's disease using publicly available consortia data on 643 836 individuals. Observationally, multifactorially adjusted Cox regression restricted cubic spline models showed that both men and women with extreme high HDL cholesterol concentrations had increased risk of any dementia and of Alzheimer's disease. Men in the 96th-99th and 100th vs. the 41st-60th percentiles of HDL cholesterol had multifactorially including APOE genotype adjusted hazard ratios of 1.66 (95% confidence interval 1.30-2.11) and 2.00 (1.35-2.98) for any dementia and 1.59 (1.16-2.20) and 1.87 (1.11-3.16) for Alzheimer's disease. Corresponding estimates for women were 0.94 (0.74-1.18) and 1.45 (1.03-2.05) for any dementia and 0.94 (0.70-1.26) and 1.69 (1.13-2.53) for Alzheimer's disease. Genetically, the two-sample Mendelian randomization odds ratio for Alzheimer's disease per 1 SD increase in HDL cholesterol was 0.92 (0.74-1.10) in the IGAP2019 consortium and 0.98 (0.95-1.00) in the ADSP/IGAP/PGC-ALZ/UKB consortium. Similar estimates were observed in sex stratified analyses.
High plasma HDL cholesterol was observationally associated with increased risk of any dementia and Alzheimer's disease, suggesting that HDL cholesterol can be used as an easily accessible plasma biomarker for individual risk assessment.
血浆高密度脂蛋白(HDL)胆固醇与痴呆风险之间的关联尚不清楚。因此,我们检验了以下假设:血浆HDL胆固醇水平升高与痴呆风险增加相关,以及这种潜在关联是否具有因果性质。
在两项基于人群的前瞻性研究,即哥本哈根普通人群研究和哥本哈根城市心脏研究(N = 111984人)中,我们首先检验了高血浆HDL胆固醇是否与任何痴呆及其亚型的风险增加相关。对男性和女性分别进行的这些分析针对包括载脂蛋白E(APOE)基因型在内的其他风险因素进行了多因素调整。其次,利用两样本孟德尔随机化方法,我们使用公开可得的关于643836人的联盟数据,检验了遗传上升高的HDL胆固醇是否与阿尔茨海默病存在因果关联。在观察性研究中,多因素调整的Cox回归受限立方样条模型显示,HDL胆固醇浓度极高的男性和女性患任何痴呆和阿尔茨海默病的风险均增加。HDL胆固醇处于第96 - 99百分位和第100百分位的男性与处于第41 - 60百分位的男性相比,在多因素调整(包括APOE基因型)后,患任何痴呆的风险比分别为1.66(95%置信区间1.30 - 2.11)和2.00(1.35 - 2.98),患阿尔茨海默病的风险比分别为1.59(1.16 - 2.20)和1.87(1.11 - 3.16)。女性的相应估计值为,患任何痴呆的风险比分别为0.94(0.74 - 1.18)和1.45(1.03 - 2.05),患阿尔茨海默病的风险比分别为0.94(0.70 - 1.26)和1.69(1.13 - 2.53)。在基因层面,在IGAP2019联盟中,HDL胆固醇每增加1个标准差,患阿尔茨海默病的两样本孟德尔随机化优势比为0.92(0.74 - 1.10),在ADSP/IGAP/PGC - ALZ/UKB联盟中为0.98(0.95 - 1.00)。在按性别分层的分析中观察到了类似的估计值。
观察性研究表明,高血浆HDL胆固醇与任何痴呆和阿尔茨海默病的风险增加相关,这表明HDL胆固醇可作为一种易于获取的血浆生物标志物用于个体风险评估。